By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics today announced revenues for the fourth quarter dropped to $45,000 from $119,000 a year ago, a 62 percent retreat.

For the three months ended Dec. 31, 2010, the company posted a net loss of $3.7 million, or $.21 per share, an 8 percent decline from a little more than $4 million, $.28 per share, from the fourth quarter of 2009.

On a non-GAAP basis, Rosetta saw a loss of $.20 per share, down from $.25 per share a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.